UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
SCHEDULE 14A
Proxy Statement Pursuant to Section 14(a) of the
Securities Exchange Act of 1934
Filed by the Registrant x Filed by a Party Other Than the Registrant ¨
Check the Appropriate Box:
| ¨ | Preliminary Proxy Statement | |||
| ¨ | Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) | |||
| ¨ | Definitive Proxy Statement | |||
| x | Definitive Additional Materials | |||
| ¨ | Soliciting Material Pursuant to §240.14a-12 | |||
Pfizer Inc. | ||||
| (Name of Registrant as Specified In Its Charter) | ||||
| (Name of Person(s) Filing Proxy Statement, if other than the Registrant) | ||||
| Payment of filing fee (Check the appropriate box): | ||||
| x | No fee required | |||
| ¨ | Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11 | |||
| (1) | Title of each class of securities to which transaction applies:
| |||
| (2) | Aggregate number of securities to which transaction applies:
| |||
| (3) | Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):
| |||
| (4) | Proposed maximum aggregate value of transaction:
| |||
| (5) | Total fee paid: | |||
| ¨ | Fee paid previously with preliminary materials. | |||
| ¨ | Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing. | |||
| (1) | Amount Previously Paid:
| |||
| (2) | Form, Schedule or Registration Statement No.:
| |||
| (3) | Filing Party:
| |||
| (4) | Date Filed:
| |||
Pfizer Inc
235 East 42nd Street, New York, NY 10017
April 11, 2011
Re: Pfizer’s Annual Meeting of Shareholders – April 28, 2011
Dear Shareholder:
We recently distributed the proxy materials for Pfizer’s Annual Meeting of Shareholders, which takes place on April 28, 2011. As I noted in my letter “To Our Stakeholders”, Pfizer met or exceeded its revenue and earnings per share goals in 2010, reporting record sales of $67.8 billion, driven by an increasingly diverse portfolio of products. In December 2010, the Board of Directors approved an 11% increase in the first quarter 2011 dividend, and in January 2011, the Board increased the funds authorized for share buybacks to $9 billion. You may view the full text of my letter* in the Proxy Statement.
I am writing to ask for your support at our Annual Meeting of Shareholders by voting your shares. Your vote is needed and valued. With the Annual Meeting only a short time away, please act today to be sure your shares are voted in accordance with your wishes. You can vote by telephone, Internet or mail. For your convenience, a duplicate proxy/voting instruction card and return envelope are enclosed, along with telephone and Internet voting instructions. In the event that two proxies/voting instruction forms are received from you, the one with the latest date will be counted.
If you have already voted, thank you for your prompt response. I appreciate your investment in Pfizer and your consideration of the matters to be presented at this year’s Annual Meeting.
Thank you for voting. We appreciate your support.
Sincerely,
Ian C. Read
| * | Not part of our proxy solicitation materials |
